Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Ironwood Pharmaceuticals, Inc. - Class A

IRWD

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Last trade $4.84
Day change -$0.015 (-0.31%)
Day range $4.50 – $4.90
Volume 1,067,767
Market cap $803M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$802.92M
Price / earnings
5.37×
Price / book
-8.26×
Price / sales
2.01×
EV / sales
2.6×
EV / EBITDA
4.11×

Profitability

Earnings per share
$0.90
Return on assets
51.49%
Return on equity
-153.95%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-3.34×
Current ratio
6.51×
Quick ratio
6.51×
Cash ratio
2.49×

Cash flow

Price / cash flow
3.91×
Price / free cash flow
3.91×
Free cash flow
$205.37M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IRWD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$133.04M$113.04M$106.51M$47.71M$122.06M$85.24M$41.14M$90.55M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$133.04M$113.04M$106.51M$47.71M$122.06M$85.24M$41.14M$90.55M
Selling, general and administrative$11.55M$11.31M$12.03M$19.29M$21.91M$16.8M$24.26M$33.59M
Research and development$28.35M$22.42M$21.94M$21.86M$22.47M$23.37M$27.43M$25.39M
Total operating expenses$39.91M$33.73M$33.93M$40.9M$46.58M$39.92M$70.25M$59.05M
Operating income$93.13M$79.31M$72.57M$6.81M$75.48M$45.32M-$29.11M$31.49M
Interest expense-$6.2M-$7.2M-$9.14M-$7.89M-$8.43M-$8.36M-$8.07M-$8.91M
Income before taxes$87.6M$73.73M$65.17M$455K$68.02M$37.82M-$36.27M$24M
Income taxes$27.76M$22.44M$24.4M$2.73M$27.94M$14.22M$1.11M$21.74M
Net income$59.84M$51.29M$40.77M-$2.28M$40.08M$23.6M-$37.39M$2.26M
Net income attributable to common shareholders$59.84M$51.29M$40.77M-$2.28M$40.08M$23.6M-$37.39M$2.26M
EBITDA$93.59M$79.76M$72.98M$7.01M$78.16M$45.54M-$10.07M$32.05M
Basic earnings per share$0.36$0.31$0.25-$0.01$0.25$0.15-$0.23$0.01
Diluted earnings per share$0.36$0.31$0.24-$0.02$0.23$0.14-$0.23$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock Up

Ironwood Pharmaceuticals reported Q3 adjusted EPS of 36 cents, beating consensus estimates of 30 cents, though revenues missed expectations at $133 million. The company raised its 2026 revenue guidance to $485-$510 million and adjusted EBITDA guidance to over $350 million, driven by strong Linzess prescription demand growth of 4.9% year-over-year. The stock rose 6.9% following the announcement.

Zacks Investment Research

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?

Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating.

Zacks Investment Research

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.

Investing.com

3 Stocks Trading Near $5 With Massive Earnings Upside

The article identifies three penny stocks trading near $5 with significant earnings growth potential in 2026. Transocean Ltd. (RIG) is expected to grow earnings by 100% driven by favorable oil market conditions. B2Gold Corp. (BTG), a junior miner, is forecast to grow earnings by 74% as mining stocks catch up with gold prices. Ironwood Pharmaceuticals Inc. (IRWD) is projected to achieve 150% earnings growth following a 40% increase in revenue guidance, though it trades above consensus price targets.

Benzinga

Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)

U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus rose after acquiring Israeli defense software, Ironwood advanced on positive FY26 guidance, and Brand Engagement Network climbed on a new vendor agreement. JPMorgan's outlook suggests continued but challenged strength in U.S. equities, with potential 10-15% corrections offset by year-end gains driven by AI-related spending.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.